FLFengtao Liu

Fengtao Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fengtao Liu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The development and validation of a risk stratification system for assessing axillary status after neoadjuvant therapy in node-positive breast cancer: a multicenter, prospective, observational study

    by Jing-Si Mei, Fei Chen, Jia-Hui Huang, Yu-Ting Tan, Yi-Wen MsD Wu, Feng-Tao Liu, Shao-Dong Qiu, Cai-Gou Shi, Yao Lu, Xue-Yan Wang, et al.

    Objective: It is not clear which procedure is most optimal for axilla after neoadjuvant therapy (NAT) in node-positive breast cancer patients. Accurately identifying patients with axillary pathologic complete response (pCR) is crucial to minimize the overtreatment of axilla. This study was designed to develop a risk stratification model for axillary pCR. Methods: In this multicenter, prospective, observational study, node-positive breast cancer patients who received NAT followed by axillary lymph node dissection (ALND) were enrolled between June 2021 and April 2024. We assessed the performance of breast shear wave elastography (SWE) utilizing virtual touch imaging quantification in determining axillary status across ultrasound (US) nodal stages following NAT. A predictive model incorporating axilla US nodal stage and breast SWE was developed using multivariate logistic regression analysis. Last, a simplified risk score was developed based on the calculated prediction probability from this model and validated in the external test cohort. Results: The axillary pCR rates were 52.53% in the training cohort (n = 257) and 51.79% in the external test cohorts (n = 195). Approximately 21.67% of US N0 cases were false negatives; 42.35% of US N1 cases were false positives. With SWE, the false negative rate was 11.53% in US N0 patients and false positive rate was 22.22% in US N1 patients. The model based on dual-modality US demonstrated strong discriminatory ability (AUC, 0.93), precise calibration (slope of calibration curve, 0.99), and practical clinical utility (probability threshold, 4.5–94.5%); the percentages of accuracy, sensitivity, and specificity were 87.94%, 88.52%, and 87.41%, respectively. Patients scoring 1 demonstrated a low axillary non-pCR rate (5.21%–6.97%), potentially reducing unnecessary ALND rate (17.12%–24.10%). Conclusions: The risk stratification model integrating axilla US and breast SWE demonstrated good performance for assessing axillary status after NAT in node-positive breast cancer and might provide guidance for less aggressive management for specific individuals.


  • Open Access

    Elastography-based AI model can predict axillary status after neoadjuvant chemotherapy in breast cancer with nodal involvement: a prospective, multicenter, diagnostic study

    by Jia-Xin Huang, Yao Lu, Yu-Ting Tan, Feng-Tao Liu, Yi-Liang Li, Xue-Yan Wang, Jia-Hui Huang, Shi-Yang Lin, Gui-Ling Huang, Yu-Ting Zhang, et al.

    Objective: To develop a model for accurate prediction of axillary lymph node (LN) status after neoadjuvant chemotherapy (NAC) in breast cancer patients with nodal involvement. Methods: Between October 2018 and February 2024, 671 breast cancer patients with biopsy-proven LN metastasis who received NAC followed by axillary LN dissection were enrolled in this prospective, multicenter study. Preoperative ultrasound (US) images, including B-mode ultrasound (BUS) and shear wave elastography (SWE), were obtained. The included patients were randomly divided at a ratio of 8:2 into a training set and an independent test set, with five-fold cross-validation applied to the training set. The authors first identified clinicopathological characteristics and conventional US features significantly associated with the axillary LN response and developed corresponding prediction models. The authors then constructed deep learning radiomics (DLR) models based on BUS and SWE data. Models performances were compared, and a combination model was developed using significant clinicopathological data and interpreted US features with the SWE-based DLR model. Discrimination, calibration and clinical utility of this model were analyzed using the receiver operating characteristic curve, calibration curve, and decision curve, respectively. Results: Axillary pathologic complete response (pCR) was achieved in 52.41% of patients. In the test cohort, the clinicopathologic model had an accuracy of 71.30%, while radiologists’ diagnoses ranged from 64.26 to 71.11%, indicating limited to moderate predictive ability for the axillary response to NAC. The SWE-based DLR model, with an accuracy of 80.81%, significantly outperformed the BUS-based DLR model, which scored 59.57%. The combination DLR model boasted an accuracy of 88.70% and a false-negative rate of 8.82%. It demonstrated strong discriminatory ability (AUC, 0.95), precise calibration ( P -value obtained by Hosmer–Lemeshow goodness-of-fit test, 0.68), and practical clinical utility (probability threshold, 2.5–97.5%). Conclusions: The combination SWE-based DLR model can predict the axillary status after NAC in patients with node-positive breast cancer, and thus, may inform clinical decision-making to help avoid unnecessary axillary LN dissection.


  • Open Access

    Deep learning combining mammography and ultrasound images to predict the malignancy of BI-RADS US 4A lesions in women with dense breasts: a diagnostic study

    by Yaping Yang, Ying Zhong, Junwei Li, Jiahao Feng, Chang Gong, Yunfang Yu, Yue Hu, Ran Gu, Hongli Wang, Fengtao Liu, et al.

    Objectives: The authors aimed to assess the performance of a deep learning (DL) model, based on a combination of ultrasound (US) and mammography (MG) images, for predicting malignancy in breast lesions categorized as Breast Imaging Reporting and Data System (BI-RADS) US 4A in diagnostic patients with dense breasts. Methods: A total of 992 patients were randomly allocated into the training cohort and the test cohort at a proportion of 4:1. Another, 218 patients were enrolled to form a prospective validation cohort. The DL model was developed by incorporating both US and MG images. The predictive performance of the combined DL model for malignancy was evaluated by sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). The combined DL model was then compared to a clinical nomogram model and to the DL model trained using US image only and to that trained MG image only. Results: The combined DL model showed satisfactory diagnostic performance for predicting malignancy in breast lesions, with an AUC of 0.940 (95% CI: 0.874–1.000) in the test cohort, and an AUC of 0.906 (95% CI: 0.817–0.995) in the validation cohort, which was significantly higher than the clinical nomogram model, and the DL model for US or MG alone (P<0.05). Conclusions: The study developed an objective DL model combining both US and MG imaging features, which was proven to be more accurate for predicting malignancy in the BI-RADS US 4A breast lesions of patients with dense breasts. This model may then be used to more accurately guide clinicians’ choices about whether performing biopsies in breast cancer diagnosis.


  • Open Access

    Does establishing a preoperative nomogram including ultrasonographic findings help predict the likelihood of malignancy in patients with microcalcifications?

    by Hongli Wang, Jianguo Lai, Jiao Li, Ran Gu, Fengtao Liu, Yue Hu, Jingsi Mei, Xiaofang Jiang, Shiyu Shen, Fengyan Yu, et al.

    Mammography (MG) is highly sensitive for detecting microcalcifications, but has low specificity. This study investigates whether establishing a preoperative nomogram including ultrasonographic findings can help predict the likelihood of malignancy in patients with mammographic microcalcification. Between May 2012 and January 2017, 475 patients with suspicious microcalcifications detected on MG underwent ultrasonography (US). The χ2 test was used to screen risk factors among the variables. Then, a multivariate logistic regression analysis was performed to identify independent predictors of malignant microcalcifications. A mammographic nomogram (M nomogram) and mammographic-ultrasonographic nomogram (M-U nomogram) were established based on multivariate logistic regression models. The discriminatory ability and clinical utility of both nomograms were compared by the receiver operating characteristics curve and decision curve analysis. The calibration ability was evaluated using a calibration curve. Among the cases, 68.2% (324/475) were pathologically diagnosed as breast cancer and 31.8% (151/475) were benign lesions. Based on multivariate logistic regression analysis, age, clinical manifestation, morphology and distribution of microcalcifications on MG and lesions associated with microcalcifications on US were confirmed as independent predictors of malignant microcalcifications. In terms of discrimination ability, the C-index of the M-U nomogram was significantly higher than that of the M nomogram (0.917 vs 0.897, p = 0.006). The bias-corrected curve was close to the ideal line in the calibration curve. Decision curve analysis suggested that the M-U nomogram was superior to M nomogram. Combining mammographic parameters with ultrasonographic findings in a nomogram provided better performance than an M nomogram alone, especially for dense breasts, which suggests the value of ultrasonographic finding for individualized prediction of malignancy in patients with microcalcifications.


  • Open Access

    Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2− breast cancers by the 2015 St. Gallen consensus classification

    by Yue Hu, Ran Gu, Jinghua Zhao, Yaping Yang, Fengtao Liu, Liang Jin, Kai Chen, Haixia Jia, Hongli Wang, Qiang Liu, et al.

    This study evaluated the distribution pattern of the Ki67-labeling index (LI) among patients at a Chinese breast cancer center, and analyzed its prognostic significance in the 2015 St Gallen consensus breast cancer classification, estrogen receptor-positive and human epidermal growth factor receptor 2-negative(ER+/HER2−)subtype. We classified 939 women with ER+/HER2− breast cancer into three groups by Ki67-LI levels, and followed their clinicopathologic characteristics and prognoses. In the 939 eligible subjects, 342 had Ki67-LI ≤10% (Ki67Low), 281 had Ki67-LI between 10 and 30% (Ki67Medium), and 316 had Ki67-LI ≥30% (Ki67High). Although the Ki67High group had less favorable clinicopathologic factors, the Ki67Medium group’s factors varied considerably. Kaplan-Meier estimates showed that disease-free survival(DFS) for the Ki67Medium group was significantly shorter than the Ki67Low group but longer than the Ki67High group. Ki67-LI had independent prognostic significance in multivariate analysis. Other diagnostic factors, including tumor size >2 cm, positive lymph nodes, and grade III disease, were significantly associated with poorer disease-free survival only in the Ki67Medium group. For patients with ER+/HER2− breast cancer, we confirmed three distinct risk patterns by Ki67-LI levels according to the 2015 St Gallen consensus. For patients with clearly low or high Ki67-LI, straightforward clinical decisions could be offered, but for patients with intermediate Ki67-LI, other factors might provide valuable information.